Comment je traite.... Un cancer du pancreas avance

[en] Median survival of advanced pancreatic cancer is about three months. Unfortunately, chemotherapy is not a curative approach. Chemotherapy improves the quality of life and overall survival compared to best supportive care. Nevertheless, as the overall survival remains disappointing, clinical research must ongoing to define better treatment regimen.

Disciplines :

Hematology

Author, co-author :

Polus, Marc ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie

Jerusalem, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale

Sautois, Brieuc ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale

Silvestre, R. M.

Fillet, Georges ; Université de Liège - ULiège > Département des sciences cliniques > Hématologie - Oncologie médicale

Language :

French

Title :

Comment je traite.... Un cancer du pancreas avance

Alternative titles :

[en] How I Treat ... An Advanced Pancreatic Cancer

Publication date :

March 2002

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

131-4

Peer reviewed :

Peer reviewed

Available on ORBi :

since 31 March 2009

Statistics

Number of views

180 (9 by ULiège)

Number of downloads

133 (4 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Evans D.B., Abbruzzese J.L., Rich T.A. (1997) Cancer of the pancreas. Cancer: principles and practice of oncology (5° ed.) , De Vita VT Jr, Helman S, Rosenberg SA. Lippincott, Philadelphia, PA; 1054-1087.
Therasse P., Arbuck S.G., Eisenhauer E.A. (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216.
Frey C., Twoney P., Keehn R. (1981) Randomised study of 5-Fu and CCNU in pancreatic cancer. Cancer 47:27-31.
Andersen J.R., Friis-Moller A., Hancke S. (1981) A controlled trial of combination chemotherapy with 5-FU and BCNU in pancreatic cancer. Scan J Gastroenterol 16:973-975.
Mallinson C.N., Rake M.O., Cocking J.B. (1980) Chemotherapy in pancreatic cancer: Results of a controlled prospective, randomised, multicenter trial. Br Med J 281:1589-1591.
Palmer K.R., Kerr M., Knowles G. (1994) Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br Med J 81:882-885.
Glimelius B., Hoffman K., Sjöden P.O. (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593-600.
Kovach S., Moertel C.G., Schutt A.J. (1974) A controlled study of combined 1,3-bis(2-chlorethyl)-1-nitrosurea and 5-fluoro-uracil therapy for advanced gastric and pancreatic cancer. Cancer 33:563-569.
Moertel C.G., Engstrom P., Lavin P.T. (1979) Chemotherapy of gastric and pancreatic carcinoma: A controlled evaluation of combination of 5 fluorouracil with nitrosureas and lactones. Surgery 85:509-513.
Cullinan S.A., Moertel C.G., Fleming T.R. (1985) Comparison of three chemotherapeutic regimens in the treatment of advanced gastric and pancreatic carcinoma. JAMA 253:2061-2067.
Cullinan S.A., Moertel C.G., Wieand H.S. (1990) A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-FU, doxorubicin, and cisplatin. Cancer 65:2207-2212.
Rougier P., Ducreux M., Douillard J.Y. (1999) Efficacy of 5FU+Cisplatin compared to bolus 5FU in advanced pancreatic carcinoma: A randomised trial from the French Anticancer Centers Digestive Group. Proc Asco , Abstract 1050; 18.
Burris H., Moore M.J., Andersen J. (1997) Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: A randomised trial. JCO 15:2403-2413.
Berlin J., Catalano P., Thomas J. (2001) A phase III study of gemcitabine in combination with 5-FU vs gemcitabine alone in patients with advanced pancreatic carcinoma: An Eastern Cooperative Oncology group (ECOG) Trial. Proc Asco , abstract 505; 20.
Di Costanzo F., Sdrobolini A., Carlini P. (2001) Gemcitabine alone or in combination with 5-FU continuous infusion in the treatment of advanced pancreatic cancer: A GOIRC randomised phase II trial. Proc Asco , abstract 612; 20.
Heinemann V., Wilke H., Mergenthaler H.G. (2000) Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 11:1399-1403.
Philip P.A., Zalupski M.M., Vaitkevicius V.K. (2001) Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 92:569-577.
Brodowicz T., Wolfram R.M., Kostler W.J. (2000) Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer. Anticancer Drugs 11:623-628.
Copur M.S., Ledakis P., Bolton M. (2001) Weekly Cisplatinum and gemcitabine in patients with locally advanced or metastatic pancreatic cancer. Proc Asco , Abstract 619; 20.
Oukkal M., Bouzid K., Mahfouf H. (2001) Gemcitabine and cisplatin in the treatment of locally advanced and/or metastatic pancreatic carcinoma. Proc Asco , Abstract 2275; 20.
Colucci G., Riccardi F., Giuliani F. (1999) Randomised trial of gemcitabine alone or with cisplatin in the treatment of advanced pancreatic cancer: A phase II multicenter study of the Southern Italy Oncology Group. Proc Asco , Abstract 961; 18.
Louvet C., André T., Liedo G. (2001) Gemcitabine-oxaliplatin (GEMOX) combination in advanced pancreatic carcinoma: A Gercor multicenter phase II study. Proc Asco , Abstract 506; 20.
Stathopoulos G., Rigatos G., Dimopoulos M. (2000) Front-line treatment of pancreatic carcinoma with gemcitabine in combination with irinotecan: Preliminary results of a multicenter phase II study. Proc Asco , Abstract 1260; 19.
Rocha Lima C., Savarese D., Bruckner H. (2000) Multicenter phase II trial of first line irinotecan and gemcitabine in patients with locally advanced or metastatic pancreatic cancer. Proc Asco , Abstract 1023; 19.
Alfonso P.G., Sancho J., Belon L. (2001) A phase II study of weekly irinotecan and gemcitabine as first line treatment in locally advanced or metastatic pancreatic cancer. Proc Asco , GOTI Study Group, Abstract 2328; 20.
Gonzalez Cao E., Salgado E., Rodriguez J. (2001) Docetaxel with gemcitabine in metastatic pancreatic cancer. Proc Asco , Abstract 2274; 20.
Van Laethem J.L., Van Maele P., Polus M. (2002) Raltitrexed and gemcitabine in advanced pancreatic carcinoma: A Belgian multicenter phase II study. Asco.
Reni M., Passoni P., Panucci M.G. (2001) Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. JCO 19:2679-2686.
Garnier C., Rebischung C., Chirpaz E. (2001) Phase II study of a combination with leucovorin, 5-FU bolus and infusion, gemcitabine and oxaliplatin in locally advanced and metastatic pancreatic carcinoma. Proc Asco , Abstract 620; 20.
Gjertsen M.K., Buanes T., Rosseland A.R. (2001) Intradermal Ras peptide vaccination with granulocyte macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 92:441-450.
Moore M.J., Hamm J., Eisenberg P. (2000) A comparison between gemcitabine and the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced pancreatic cancer. Proc Asco , Abstract 930; 19.
Lersch C., Van Cutsem E., Amado R. (2001) Randomised phase II study of SCH 66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas. Proc Asco , Abstract 608; 20.
Abbruzzese J.L., Rosenberg A., Xiong Q. (2001) Phase II study of Anti-epidermal growth factor receptor (EGFR) Antibody Cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proc Asco , Abstract 518; 20.
Safran H., Ramanathan R., Schwartz J. (2001) Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Proc Asco , Astract 517; 20.